BACKGROUND:At present, the main research fields about coronary stents are the whole degradation biological materials with high biocompatibility and drug control ed release systems.
OBJECTIVE: To evaluate the safety after the two novel biodegradable stents implanted in coronary arteries in porcine models.
METHODS:The normal ful y biodegradable stents were made up of the poly-L-lactide and the antiproliferative drugs paclitaxel, and the novel biodegradable stents were added in amorphic calcium phosphate at the basis of normal biodegradable stents. (1) Five normal ful y biodegradable stents were randomly implanted into the coronary arteries of five porcines, and five novel biodegradable stents were randomly implanted into the coronary arteries of the remaining five porcines by coronary angiography. The blood biochemistry and C-reactive protein levels were measured pre-operation and at 28 days after operation. Coronary angiography was utilized to observe the lumen unobstructed at 28 days after surgery. (2) Under a microscope, seven normal ful y biodegradable stents and seven novel biodegradable stents were implanted into right external iliac arteries of 14 rabbits. Blood urea nitrogen and creatinine levels were measured before surgery and at 28 days after operation.
RESULTS AND CONCLUSION:At 28 days after operation, there were no significant changes in porcine glutamic-pyruvic transaminase, aspartate aminotransferase, triacylglycerol, total cholesterol, low density lipoprotein and C-reactive protein levels compared with that before operation, but urea nitrogen and creatinine levels were significantly higher than that before operation (P<0.05). The result of coronary angiography showed that no in-stent thrombosis or stenosis was detected in either group. There was no significant difference in urea nitrogen and creatinine levels in both groups. These results suggested that it is safe and compatible after the two novel biodegradable stents implanted in coronary arteries of porcine models, and the stents had good histocompatibility.

Objective To observe effect of Compound Ruikangxin Capsula(CRC) on anxiety-like symptoms of morphine-withdrawal rats and investigate its mechanism.Methods The elevating doses were applied to validating anxiety-like behavior in SD male rats with sc morphine for 10 d.Treatments with ig administration of CRC(100,200,and 300 mg/kg) and buspirone(15 mg/kg) were performed during 1—3 d morphine withdrawal(twice every day).The plus elevated maze was applied to validating anxiety-like symptom in rats.The expression levels of synaptophysin were detected on hippocampus in groups by immunohistochemitry 72 h after sc morphine.Results As compared with the control group,animals treated with CRC(200 and 300 mg/kg) and buspirone had higher ratio of entry into open arm (P

Objective To investigate the related factors of anxiety in patients undergoing liver puncture,so as to provide better clinical care and psychological intervention for patients to ensure the successful completion of liver puncture. Methods From January 2008 to January 2014,310 cases of patients from the Third People's Hospital of Shenzhen with liver puncture were selected as the research object. The patients' general condition and self rating Anxiety Scale were investigated. Results The SAS score of the patients who would undergo liver puncture was(47.25±0.44)points,and the incidence of anxiety symptoms was 91.3%. The results of univariate and multivariate analysis showed that the effect of patients with anxiety before liver biopsy can explain the variation of the size of the corresponding factors:whether accompanied by family members, payment methods,awareness of the disease,ear of liver failure,the education level,and gender(β' =0.617, 0.352,0.114,0.102,0.082、0.043;P < 0.05). Conclusions Before the liver puncture,the patients show a state of anxiety. The main factors affecting the anxiety status are whether to have family members,to pay for the disease,to understand the disease,to worry about the failure of liver failure,the degree of education and gender medical staff should provide targeted nursing intervention for patients to alleviate anxiety and promote rehabilitation on the basis of the above factors and the relevant circumstances.

Consecutively hospitalized patients with confirmed coronavirus disease 2019 (COVID-19) in Wuhan, China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin-angiotensin system inhibitor (RAS-I) and the outcome of this disease. Associations between the use of RAS-I (angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)), ACEI, and ARB and in-hospital mortality were analyzed using multivariate Cox proportional hazards regression models in overall and subgroup of hypertension status. A total of 2771 patients with COVID-19 were included, with moderate and severe cases accounting for 45.0% and 36.5%, respectively. A total of 195 (7.0%) patients died. RAS-I (hazard ratio (HR)= 0.499, 95% confidence interval (CI) 0.325-0.767) and ARB (HR = 0.410, 95% CI 0.240-0.700) use was associated with a reduced risk of all-cause mortality among patients with COVID-19. For patients with hypertension, RAS-I and ARB applications were also associated with a reduced risk of mortality with HR of 0.352 (95% CI 0.162-0.764) and 0.279 (95% CI 0.115-0.677), respectively. RAS-I exhibited protective effects on the survival outcome of COVID-19. ARB use was associated with a reduced risk of all-cause mortality among patients with COVID-19.
Angiotensin Receptor Antagonists/therapeutic use* ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use* ; COVID-19 ; Humans ; Hypertension/drug therapy* ; Renin-Angiotensin System ; Retrospective Studies